Review Highlights MSC Plasticity for Targeted Cancer and Inflammatory Therapies
A new comprehensive review published in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer examines the factors that determine the immunophenotypic plasticity of mesenchymal stem cells (MSCs). Authored by Reyhaneh Tamimi, Mohammad Tafazzoli-Shadpour, and Massoud Vosough, the paper titled "Determinants of MSC immunophenotypic plasticity: From canonical priming to emerging strategies for cancer and inflammatory therapies" synthesizes current knowledge on how these multipotent stromal cells can be directed toward either pro-inflammatory (MSC1) or anti-inflammatory (MSC2) states. The work, available at the ScienceDirect page, offers a framework for deterministic programming of MSC phenotypes to enhance therapies in oncology and chronic inflammation.
MSCs, derived from sources such as bone marrow, adipose tissue, umbilical cord, and placenta, possess self-renewal capacity and multilineage differentiation potential. Their immunomodulatory functions arise through paracrine signaling and direct cell-cell interactions with immune populations including T cells, B cells, natural killer cells, and macrophages. The review emphasizes that MSC phenotypes exist along a continuum rather than as strict binary states, with outcomes influenced by stimulus type, dose, duration, and microenvironmental context.
Canonical Priming Approaches and Their Mechanisms
The authors systematically categorize established priming methods. Cytokines and chemokines, Toll-like receptor (TLR) agonists, autophagy regulators, pharmacological agents, and bacterial components form the core of canonical strategies. For instance, combinations of interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) or specific TLR3/TLR4 activation can polarize MSCs toward the MSC1 phenotype, characterized by enhanced secretion of pro-inflammatory mediators that support anti-tumor immunity. Conversely, other cytokine milieus or pharmacological interventions favor MSC2 polarization, promoting immunosuppression beneficial for autoimmune and inflammatory conditions.
These approaches leverage well-characterized signaling pathways to alter gene expression and secretome profiles. The review notes that MSC-derived exosomes largely retain the immunomodulatory properties of their parent cells, opening avenues for cell-free therapies with advantages in storage, reduced immunogenicity, and targeted delivery of nucleic acids, proteins, and lipids.
Photo by Markus Spiske on Unsplash
Emerging Non-Canonical Stimuli Expand the Toolkit
Beyond traditional agents, the paper explores innovative determinants including natural and inorganic compounds, metal ions, engineered biomaterials, and patient-derived immunological components. Biophysical cues such as substrate stiffness, pore size, porosity, and topography, alongside biochemical signals from growth factors and bioactive molecules, profoundly influence MSC polarization and the properties of their secreted vesicles.
These non-canonical strategies provide fresh opportunities to fine-tune MSC behavior for specific clinical contexts. For example, certain metal ions or biomaterial scaffolds can direct polarization without the variability sometimes observed with cytokine-based methods. The authors highlight how such approaches could improve consistency in good manufacturing practice (GMP)-compatible protocols.
Dual Roles in Cancer and Inflammatory Disease
MSCs exhibit context-dependent effects in the tumor microenvironment. MSC1-like phenotypes can enhance anti-tumor immunity through CD8+ T-cell recruitment, macrophage repolarization, and angiogenesis inhibition, offering potential as standalone or combinatorial agents with chemotherapy. MSC2 phenotypes, while useful in suppressing excessive inflammation, may inadvertently support tumor progression in some settings.
In inflammatory diseases, MSC2 polarization supports tissue regeneration and resolution of chronic inflammation, whereas MSC1 induction may prove valuable in specific acute or severe inflammatory states. The review stresses the need to interpret findings through the lens of phenotypic plasticity rather than fixed categories.
Photo by Mika Baumeister on Unsplash
Challenges in Standardization and Clinical Translation
Despite promising preclinical data, barriers to translation persist. Variability in MSC source, donor characteristics, and priming conditions complicates reproducibility. The authors call for deeper mechanistic studies on signaling crosstalk, optimized dosing regimens, and validation in complex three-dimensional tumor models that better recapitulate the in vivo microenvironment.
Future directions include integration of single-cell analytical technologies and advanced biomaterial engineering to achieve personalized MSC-based interventions. Combination therapies that pair primed MSCs with existing immunotherapies or chemotherapeutics represent a particularly active area for investigation.
Implications for Research and Therapeutic Development
This review provides researchers and clinicians with a structured overview of both established and emerging priming modalities. By bridging canonical and non-canonical approaches, it underscores opportunities to harness MSC plasticity for improved outcomes in cancer immunotherapy, regenerative medicine, and treatment of inflammatory disorders. The work encourages interdisciplinary collaboration among immunologists, materials scientists, and translational clinicians to accelerate progress from bench to bedside.
Readers interested in related academic opportunities in stem cell biology and immunology may explore current openings through specialized job platforms focused on higher education and research positions.
